Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6333178 | 0.99 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL762432 | 0.91 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6359510 | 0.86 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL5811642 | 0.85 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL6337323 | 0.84 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL5811129 | 0.84 | CNR1 (0.86) | CNR1CNR2 | |
| SCHEMBL27591744 | 0.84 | CNR1 (0.86) | CNR1CNR2 | |
| SCHEMBL5807672 | 0.83 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL6335075 | 0.83 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL6342015 | 0.83 | CNR1 (0.66) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006060190-A2 | IMIDAZOLE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060203-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DEMENTIA AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060199-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060202-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2005099705-A2 | PREPARATION OF IMIDAZOLE DERIVATIVES AND METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-27 | — | — | WO | claimed |
| CN-1599724-A | Imidazole-4-carboxamide derivatives, their preparation and use in the treatment of obesity | BAYER PHARMACEUTICALS CORPORAT (US) | 2005-03-23 | — | — | CN | claimed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | claimed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | claimed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| CN-1865248-A | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2006-11-22 | — | — | CN | disclosed |
| WO-2006060203-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DEMENTIA AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060199-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060202-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| US-6960601-B2 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| CN-1599724-A | Imidazole-4-carboxamide derivatives, their preparation and use in the treatment of obesity | BAYER PHARMACEUTICALS CORPORAT (US) | 2005-03-23 | — | — | CN | disclosed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CNR1 405/4885CNR2 340/4885 |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CNR1 405/4885CNR2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.